Biotechs Continue to Underperform (IBB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Leerink Partners Reiterates Outperform on BioMarin Pharma (BMRN) Following Mixed Ph. 3 Data Results
March 21, 2016 1:17 PM EDTLeerink Partners reiterated an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's mixed PEG-PAL Ph. 3 data. In study '302, blood Phe elevated to near-baseline levels (1385.7 uM) upon discontinuation vs. pts. continuing PEG-PAL treatment (527.2 uM) (p... More
Leerink Partners Cuts Price Target on Alexion Pharma (ALXN) to $216; Reiterates Outperform
March 18, 2016 6:48 AM EDTLeerink Partners maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $216.00 (from $217.00). Conviction about the company is based on a positive outlook for Soliris [aHUS, PNH] and its potential in existing and new indications, as well as... More
